The Impact of Artificial Intelligence on Value-Based Care in Orthopaedics

By Michael Awood

October 6, 2023

AI in Healthcare, AI in Orthopaedics, Value-Based Care, Patient Outcomes, Machine Learning, Ethical Considerations, Medical Education, Cost Savings, Risk Prediction, Decision Making

In healthcare, artificial intelligence has made considerable strides. It has the potential to enhance prediction, diagnosis, and decision-making. Researchers in orthopaedic surgery, where AI technologies have the potential to alter the discipline, have also seen this.

They can apply artificial intelligence in orthopaedics to find trends in data. Predicting patient risk potential or bad occurrences, for example, offers clinicians with crucial information. Despite the label “experimental,” there is mounting evidence that AI is successful and suitable for widespread use.

AI can help physicians and patients collaborate in the next steps. This points to a more cooperative intelligence. Physicians can give patient-specific risk-benefit ratios by feeding patient-reported outcomes into machine-learning algorithms. Doctors can use machine-learning algorithms to expect the results or advantages of arthroplasty surgery. However, we need further research to determine how these choice aids improve outcomes and provide value.

AI use in healthcare is fraught with ethical, legal, regulatory, and practise considerations. How should we get patients’ consent for AI-enabled robotic-assisted procedures? Surgeons must work with programmers to verify that the algorithm outputs match the demands of the patients.

It also poses questions regarding the current medical education programme, ultimately suggesting a redesign. Future professionals must learn to interact with and adapt to this technology for safe use in clinical settings.

However, there is a significant value proposition for AI in healthcare, particularly in terms of cost. AI technologies have the potential to reduce expenses by saving time and resources. These also impact patients’ experiences and outcomes. Getting clinician buy-in for the cultural shift, as well as assessing the initial cost, are essential concerns to balance against these potential savings.

AI has enormous potential in orthopaedics. To explore how artificial intelligence may aid orthopaedic patients, we need to test and assess it in clinics, prioritising its worth. According to the article, value is determined by weighing the advantages of new instruments against their entire expenses.

 

Cover image: stefamerpik on freepik

Reference url

Recent Posts

orphan drug designation zoci
Orphan Drug Designation Zoci Enhances Treatment Prospects for Pulmonary Neuroendocrine Carcinomas

By João L. Carapinha

July 1, 2026

The European Medicines Agency has granted orphan drug designation for zocilurtatug pelitecan, an investigational DLL3-targeted antibody-drug conjugate, based on ...
Belgium Fast Access Medicines
Belgium Fast Access Medicines Revolutionize Treatment for IgA Nephropathy

By João L. Carapinha

July 1, 2026

Belgium Fast Access Medicines has moved from policy to practice. Authorities have granted temporary reimbursement to Atrasentan, the first therapy approved under the new Early and Equitable Fast Access procedure, offering quicker hope to patients with IgA nephropathy while anchoring the country’s...
Retracted Trial Publication
Retracted Trial Publication Undermines Support for Avacopan in AAV Treatment

By João L. Carapinha

July 1, 2026

The Retracted Trial Publication of the ADVOCATE study has eliminated the central evidence that supported approval of Tavneos (avacopan) for severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis (AAV). At the request of two lead academic authors, the